Welcome to our dedicated page for JANUS LIVING news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JANUS LIVING stock.
The news page for JanOne Inc. (historically Nasdaq: JAN) provides an archive of company announcements and press releases that document its transition into ALT5 Sigma Corporation and the evolution of its business focus. These news items explain how the organization moved from being described primarily as a biopharmaceutical company focused on non-addicting pain treatments to a multidisciplinary entity combining healthcare initiatives with a growing fintech platform centered on blockchain-powered digital asset services.
Readers will find coverage of the company’s confirmation of its name change to ALT5 Sigma Corporation and ticker change to ALTS, reflecting a strategic realignment to focus on its recently acquired ALT5 Sigma fintech business as a core engine for revenue growth. News articles describe the acquisition and integration of ALT5 Sigma Inc., the company’s addition to the Russell Microcap Index, and subsequent developments such as the launch of the ALT5 Settlement Platform, the introduction of a prepaid Visa card integration, and reported transaction volumes processed by ALT5 subsidiaries.
The archive also includes updates on leadership appointments related to the fintech business, such as the naming of a Chief Revenue Officer and President for ALT5 Sigma, as well as communications about the company’s ongoing biotech activities aimed at addressing the opioid crisis. Earlier releases highlight JanOne’s efforts to develop non-addicting pain treatments and its dedication to funding innovation, technology, and education in this area.
By reviewing the JAN news feed, investors and researchers can trace key milestones, including the acquisition of ALT5 Sigma, strategic realignment decisions, and subsequent product and platform launches in digital payments and digital asset trading. Because the active Nasdaq ticker has changed from JAN to ALTS, this page serves as a historical record of announcements made under the JAN symbol, complementing more recent disclosures filed under the ALT5 Sigma Corporation identity.
JanOne Inc. (Nasdaq: JAN) has entered a definitive agreement to sell its subsidiary ARCA Recycling to CFO Virland Johnson for approximately $25 million. This move is part of JanOne's strategy to focus on its core life science assets. The transaction is set to close by August 18, 2021, with immediate payments of $7.5 million and an additional $17.5 million via a subordinated promissory note at 6% interest. Proceeds will support a pivotal Phase 2b trial for the company's lead candidate, JAN101, aimed at treating peripheral artery disease.
JanOne Inc. (Nasdaq: JAN) announced the successful closing of a securities offering, generating $6.0 million in gross proceeds by selling 571,428 shares at $10.50 each to institutional investors. The funds will be allocated for working capital and to plan clinical trials for JAN101, its lead drug candidate aimed at treating peripheral artery disease affecting over 8.5 million Americans. The offering was facilitated by A.G.P./Alliance Global Partners and conducted under a previously filed shelf registration statement.
JanOne Inc. (NASDAQ: JAN) announced a securities purchase agreement to sell 571,428 shares at $10.50 each, raising gross proceeds of $6 million. The offering is part of a registered direct offering and is expected to close around February 2, 2021, pending customary conditions. A.G.P./Alliance Global Partners is the sole placement agent. JanOne focuses on non-addictive pain relief treatments, with its lead candidate, JAN101, undergoing Phase 2b trials for peripheral artery disease, affecting over 8.5 million Americans. More details can be found on their website.
JanOne Inc. (Nasdaq: JAN) has initiated the production of JAN101 under cGMP for Phase 2b trials targeting Peripheral Artery Disease (PAD) and potential treatment for Covid-19 vascular complications. The first production batch will consist of 250,000 sustained release tablets. The Phase 2b trial is expected to commence in early 2021. With no effective treatments for PAD currently available, JAN101 aims to improve vascular function and reduce pain. Positive results from prior studies underline its potential in addressing severe pain conditions.
JanOne (Nasdaq: JAN) announced its September 2020 Shareholder Letter, detailing corporate and clinical developments. Key highlights include FDA authorization for the investigational new drug (IND) for sodium nitrite tablets and the completion of JAN101's formulation for GMP manufacturing. The company has also appointed new scientific advisors and secured a bottling partner for upcoming clinical trials. CEO Tony Isaac emphasized the company's transition to biopharma and the potential of JAN101 for treating peripheral artery disease and COVID-19 complications.
JanOne Inc. (Nasdaq: JAN) announced a strategic review process for its legacy businesses, particularly its recycling segment. This initiative follows interest from potential buyers. CEO Tony Isaac emphasized the focus on advancing their lead candidate, JAN101, for treating peripheral artery disease (PAD) and related complications from Covid-19. The company aims to maximize shareholder value through these transactions, although no guarantees on successful negotiations or terms have been established. JAN101 has shown positive results in trials, with further studies expected in early 2021.
JanOne Inc. (NASDAQ: JAN) has confirmed the stability of its developmental batch of JAN101, a treatment for peripheral artery disease (PAD). The company is set to commence GMP production to support Phase 2b trials slated for early 2021. Additionally, JanOne is finalizing an IND application for JAN101 aimed at treating Covid-19 vascular complications. The partnership with Eurofins CDMO ensures the integrity of clinical trial batches. Both clinical trials for PAD and potential Covid-19 treatment are crucial for the company’s future growth and market presence.
JanOne Inc. (Nasdaq: JAN) has selected a leading bottling and labeling partner for its investigational drug, JAN101, aimed at treating vascular complications from Covid-19 and Peripheral Artery Disease (PAD). The IND application for JAN101 is expected to be submitted to the FDA soon, with Phase 2b trials for PAD scheduled to start in early 2021. The sodium nitrite-based JAN101 demonstrated promising results in earlier studies, showing potential to improve blood flow and reduce inflammation. The company's strategy focuses on prioritizing GMP manufacturing to ensure timely clinical product availability.
JanOne Inc. (Nasdaq: JAN) has completed its initial engineering batch of JAN101, a proprietary sodium nitrite compound aimed at treating Peripheral Artery Disease (PAD) and potential Covid-19 vascular complications. Following positive Phase 1 and 2a trial results, the company plans to submit an investigational new drug application for Covid-19 treatments soon. JanOne anticipates starting Phase 2b trials for PAD in early 2021 and expects to deliver 250,000 doses within 30 days of production start, scaling up to 20 million doses by next year.
JanOne Inc. (Nasdaq: JAN) announced a teleconference on August 25, 2020, at 4:15 PM ET to discuss updates on its lead drug candidate, JAN101. JAN101 targets peripheral artery disease (PAD) and may help with COVID-19 vascular complications. The drug has shown positive results in Phase 1 and 2a trials, with a pivotal Phase 2b study planned for early 2021. The global PAD market is projected to grow from $36.1 billion in 2017 to $52.0 billion by 2022. The company is also preparing an IND package for FDA submission to explore COVID-19 treatment applications.